Module 6 After the survey TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass.

Slides:



Advertisements
Similar presentations
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
Advertisements

UNDP RBA Workshop on MDG-Based National Development Strategies Module 4: Health Strategies UN Millennium Project February 27-March 3, 2006.
MICS4 Survey Design Workshop Multiple Indicator Cluster Surveys Survey Design Workshop Household Questionnaire: Insecticide Treated Nets and Indoor Residual.
MICS4 Survey Design Workshop Multiple Indicator Cluster Surveys Survey Design Workshop Questionnaire for Children Under Five: Malaria.
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,
0 - 0.
Opportunities. Shift in Perspective for Infectious Disease Control (Porter et al 1999 Health Policy and Planning 14: ) From: Disease specificity.
Neglected Tropical Diseases and Malaria: The need for mapping.
SADC Course in Statistics Choosing appropriate methods for data collection.
Older People with Dementia in Acute Care: K ey messages from the NAO report Paul Forte The Balance of Care Group
Monitoring the impact of vaccination on rubella and CRS Susan E. Reef, MD 11 th Annual Meeting The Measles and Rubella Initiative Sept. 19, 2012.
Module 2 Eligibility for a TAS TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of.
Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
Module 10 Field work TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug.
Module 5 Diagnostic tests
1. 2 GUIDELINES 1. Identify the variable(s) of interest (the focus) and the population of the study. 2. Develop a detailed plan for collecting data. If.
5-1-1 Unit 1: Introduction to the course and to behavioural surveillance.
Unit 1. Introduction TB Infection Control Training for Managers at the National and Subnational Levels.
Development of Schistosomal School-Based Health Education Model for Yemeni Schoolchildren Hassan K. Bassiouny MD, Dr.PH., Tropical Health Dept. High Institute.
MDR-TB GLOBALLY AND IN THE REGION 2013 Dr Samiha Baghdadi Medical officer – STB WHO – EMRO Cairo March 2014.
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 4 Survey design.
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 1 Background.
Promoting Rational Drug Use in the Community Monitoring and evaluation.
Improving diagnosis TB laboratory strengthening.
Internal Control–Integrated Framework
Addition 1’s to 20.
Feb 2011 Dr Guada Lopez Marti Pediatric Infectious Diseases Marshall University.
Donald T. Simeon Caribbean Health Research Council
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
Malaria Elimination in Zanzibar. Introduction Dramatic declines in malaria morbidity and mortality over the last decade (prevalence remained
Module 3 Evaluation unit
Malaria in Zambia A refresher Scope of Presentation  Background on Malaria  Overview of malaria in Zambia  Interventions  Impact  Active Case.
Module 8 Survey sample builder
Dr Ahmed Jamsheed Mohamed WHO South East Asia Regional Office 9-11 February 2015.
Eliminating Lymphatic Filariasis in the Americas A Winnable Battle Center for Global Health Division of Parasitic Diseases and Malaria.
Module 9 Timetable, budget and administration TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological.
Post-MDA surveillance ( including xeno-monitoring) Krishnamoorthy K. Vector Control Research Centre Pondicherry India.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
RANJAN BANERJEE BIOL 062 NOVEMBER 20 TH 2008 Lymphatic Filariasis.
Lymphatic Filariasis By Morgan McBride.
Unit 10. Monitoring and evaluation
Roadmap Progress Report 2011 Zambia SARN-RBM PARTNERS ANNUAL CONSULTATIVE MEETING, JULY 2011.
EPIDEMIOLOGY DENGUE, MALARIA Priority Areas for Planning Dengue Emergency Response 1. Establish a multisectoral dengue action committee.
Module 7 Verification of elmination TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment.
Assessing the Feasibility of Continuous Net Distribution in Kenya using Community Based Approach.
Filariasis Mae Marcattilio-McCracken
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
21/4/2008 Evaluation of control measures 1. 21/4/2008 Evaluation of control measures 2 Family and Community Medicine Department.
Unit 6: Specialised Techniques: Anti-Microbial Resistance Monitoring and Assessment of STI Syndrome Aetiologies #4-6-1.
Progress Report: National LF and STH Programme in Nepal
Progress report: the national LF and STH programme in Thailand By Sunsanee Rojanapanus, Dr. Thitima Wongsaroj 2014 RPRG Meeting WHO Region.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia & Dr. Michael Lynch Epidemiologist.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia.
Objectives of Lipa malaria elimination course 2014 Give an account on the historical background on malaria control and elimination, including current concepts.
CASE DETECTION by Dr Mikhail Ejov WHO Training in Malaria Elimination in the Greater Mekong Sub-Region, August 2015, Chiang Mai Thailand 1.
Mohamed Faisal 2014 RPRG Meeting WHO Region.  Geography and Population ◦ Total population: 371,507 (Census 2006) ◦ Ecological zones – next slide  Political.
Working to overcome the global impact of neglected tropical diseases Documenting the achievement of elimination as a public health problem GPELF dossier.
Lymphatic Filariasis Chelsae Dumbauld.
1 Disaster epidemiology Professor Vilius Grabauskas Kaunas University of Medicine, Kaunas, Lithuania NATO supported advanced research workshop, Kaunas,
SMC+ ? Prudence Hamade and Sylvia Meek ACCESS-SMC Partners’ Meeting, January 2016, Kampala.
World Health Organization
STAC36 - March 2014 Design and Evaluation of a Health Educational Board Game for the Control of Soil Transmitted Helminthiasis among Primary School.
APPMG December 17, 2008 Presented by Dr. John P. Rumunu (MPH, MB.BS)
Where we could be by 2015 and how to get there
Déirdre Hollingsworth University of Warwick
Training Workshop – Module 3
Louise A. Kelly-Hope, Harriet J. Blundell, Cara L. Macfarlane, David H
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study  Michael A Irvine, PhD, Wilma A Stolk, PhD, Morgan.
Professor Jack Lambert
Presentation transcript:

Module 6 After the survey TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 6 After the survey

Learning objectives By the end of this module, you should understand the actions required after a TAS: 1.Interpreting the result of the survey 2.Reporting to decision-makers and the GPELF 3.Following up positive cases 4.Post-MDA surveillance Slide 2

Module 6 After the survey Overview  Actions required by programme managers  Interpret the result  Report to decision-makers and the GPELF  Follow up positive cases  Conduct post-MDA surveillance Slide 3

Module 6 After the survey Interpreting the results  If there is still a potential focus of infection in the EU, a plan should be made to address this issue. Programme managers may decide to conduct focal treatment even though MDA has stopped.  Other neglected tropical diseases, such as soil-transmitted helminthiasis or onchocerciasis, in the EU may still require control after MDA for LF has stopped. An appropriate programme should be planned to continue distribution of the necessary medicines. Slide 4 If the number of positive results is at or below the established critical cut-off, the EU can stop MDA.

Module 6 After the survey Interpreting the results  At least two more rounds of MDA should be conducted before repeating the TAS.  After two more rounds of effective MDA, the eligibility of the EU for conducting a TAS should be assessed again. Slide 5 If the number of positive results is greater than the established critical cut-off, the EU should continue MDA.

Module 6 After the survey Interpreting the results: example Slide 6 What is the recommendation for an EU with the following characteristics and outcome of the TAS?  Net school enrolment ratio: 78%  Primary vector: Culex  Total population of 6–7-year-old children:  Total number of primary schools: 386  Design of survey:  Sample size: 1552  Number of clusters: 38  Critical cut-off: 18  Results of TAS: 14 children positive by ICT; all positive cases in two schools

Module 6 After the survey Possible reasons for failing a TAS Slide 7  Irregular MDA  Inadequate epidemiological drug coverage  Distribution failures  Failure to adhere to directly observed treatment  Poor quality of generic drugs  Population migration or previously undetected foci of infection  Systematic non-compliance

Module 6 After the survey Systematic non-compliance Slide 8  Failure of a certain individuals to take distributed drugs regularly during any round of MDA.  These individuals may continue to be a reservoir of microfilariae.  Even if recommended drug coverage is achieved, systematic non-compliance may contribute to perpetuating transmission of LF.

Module 6 After the survey Addressing systematic non-compliance Slide 9  Targeted MDA designed to capture systematically non- compliant individuals  Social mobilization strategies targeting non-compliant individuals  Revised health education messages

Module 6 After the survey Reporting to decision-makers and the GPELF Slide 10  Decision-makers in the country (i.e. government) should be informed of the result of a TAS in order to make an appropriate decision to stop or continue MDA.  As a significant decision will be made on the basis of the outcome of the survey, national programme managers should also inform WHO and RPRG of the results and obtain specific advice if necessary. TAS Submit report to WHO/RPRG RPRG endorses results Post-MDA surveillance

Module 6 After the survey Following up positive cases Slide 11  Positive cases should be treated with one of the following regimens:  A single dose of a combination of albendazole (400 mg) and ivermectin (150–200 μg/kg) in areas where onchocerciasis is co-endemic  A single dose of a combination of albendazole (400 mg) plus diethylcarbamazine (6 mg/kg) or diethylcarbamazine (6 mg/kg) alone for 12 days in areas where there is no onchocerciasis  Programme managers may choose to test for Mf during the peak circulation time to follow up positive cases.  Residence can be ascertained to detect any significant migration in the area that could affect the impact of MDA rounds.  This should be done before positive cases are treated.  If resources allow, programme managers should conduct follow-up surveys in communities with antigen- or antibody-positive children to obtain additional information on potential residual transmission.

Module 6 After the survey Slide 12 Following up positive cases

Module 6 After the survey Post-MDA surveillance Slide 13 The success of a LF elimination programme depends on careful monitoring after MDA has stopped. Current WHO recommendations:  Periodic surveys: repeat TAS twice at interval of 2–3 years.  Ongoing surveillance (e.g. surveying military recruits, blood donors, hospitalized patients) Mapping Mf or Ag≥1% TAS Surveillance Baseline MDA Follow-up [Eligibility] Mid-term (optional) Yes M&E Pass Fail

Module 6 After the survey Potential future surveillance strategies Slide 14  New approaches to post-MDA surveillance will depend on diagnostic tools that are yet to be fully developed or standardized.  These include antifilarial antibody testing and xenomonitoring.

Module 6 After the survey Antifilarial antibody testing Slide 15  Monitoring antibody responses may be a useful method for detecting recrudescence of infection.  Antibody testing can be performed with dried filter paper blood spots.  Filter paper blood spots collected during the TAS can be used to establish a baseline for surveillance.

Module 6 After the survey Antifilarial antibody testing Slide 16 Source: Gass K et al. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate Bancroftian filariasis. PLoS Neglected Tropical Diseases 2012; 6(1):e1479.

Module 6 After the survey Xenomonitoring Slide 17  Direct assessment of parasites in vector mosquitoes by polymerase chain reaction (PCR) techniques may be useful for measuring parasite prevalence in humans in the same community.  While xenomonitoring may be useful, more research is needed to find feasible methods for sampling and testing mosquitoes.